In a breakthrough that could reshape future Alzheimer’s treatments, scientists at the Icahn School of Medicine at Mount Sinai have identified a way to reverse damage to the brain’s blood vessels caused by the APOE4 gene, the strongest genetic risk factor for the disease.
How APOE4 Harms the Brain
For years, doctors have known that people who carry the APOE4 variant experience accelerated deterioration of the tiny blood vessels that supply the brain. The new research shows that APOE4 forces pericytes—cells that normally keep these vessels stable—to turn into scar‑forming cells. Those scarred vessels thicken and trap misfolded protein clumps called amyloid, which are the primary target of current Alzheimer’s drugs.
Blocking TGF‑beta Reverses Damage in Mice
The Mount Sinai team found that inhibiting a protein called TGF‑beta, which regulates tissue repair, protects pericytes from this harmful transformation. In mouse models, the blockade not only preserved vessel function but also reversed existing cerebrovascular degeneration linked to APOE4.
“Damage to the brain’s blood vessels is not simply a late consequence of Alzheimer’s disease; it is a biologically active process caused by APOE4 that may be reversible,” said co‑author Joel Blanchard in a statement. “These findings reveal new therapeutic targets for preserving vascular function and limiting amyloid accumulation.”
Implications for Future Therapies
The findings were published in the journals Cell and Cell Stem Cell. By highlighting a reversible step in the disease pathway, the work suggests that drugs aimed at TGF‑beta or related pathways could complement existing amyloid‑targeting treatments, potentially slowing or even halting disease progression.
Other Promising Research Highlighted
In related health news, an early‑stage trial of Gilead Sciences’ CAR T‑cell therapy, anito‑cel, showed deep and durable responses in patients with hard‑to‑treat multiple myeloma. All 38 participants responded, with nearly 80% achieving a complete response and more than half remaining progression‑free after two years.
Additionally, MIT researchers reported a non‑invasive method to identify senescent cells—old cells that no longer divide but fail to die—using Raman microscopy. The technique creates unique “barcodes” for these cells, paving the way for future diagnostic tools that could detect age‑related disorders without harming tissue.
These advances underscore a growing focus on precision medicine and the importance of early detection and targeted treatment in combating both neurodegenerative and age‑related diseases.
Original reporting: Appleton, WI News Feed (HLL/CB) — read the source article.
